指南与共识乳腺癌

乳腺癌PARP抑制剂临床应用专家共识(2025版)

[Expert consensus on the clinical application of PARP inhibitors in breast cancer (2025 edition)].
指南 / 共识 · Zhonghua Zhong Liu Za Zhi · 2026-01-01

中国发病率持续攀升的乳腺癌治疗中,PARP抑制剂在BRCA1/2突变乳腺癌展现显著疗效,通过合成致死效应提供精准治疗。中国抗癌协会等多机构组织专家基于最新循证证据撰写本共识,规范PARP抑制剂的临床应用与安全性管理,为临床实践提供指导。

要点

  • PARP抑制剂在BRCA1/2突变乳腺癌中通过合成致死效应显示显著疗效。
  • 奥拉帕利、氟唑帕利等PARP抑制剂已获批用于临床治疗。
  • 共识针对PARP抑制剂规范应用和安全性管理提出指导意见。

核心结论

  • PARP抑制剂在BRCA1/2突变乳腺癌治疗中展现显著疗效,共识为其规范应用与安全性管理提供指导。

研究设计与样本

  • 中国抗癌协会肿瘤药物临床研究专业委员会、国家抗肿瘤药物临床应用监测专家委员会、国家肿瘤质控中心乳腺癌专家委员会联合北京市肿瘤治疗质量控制和改进中心肿瘤化疗质控专家委员会共同组织国内肿瘤专家及跨学科专家撰写。

主要发现

  • PARP抑制剂作为靶向DNA损伤修复通路的新型抗肿瘤药物,通过特异性抑制肿瘤细胞DNA修复产生合成致死效应。
  • 奥拉帕利、氟唑帕利等PARP抑制剂已获批用于临床治疗。

关键数值与推荐

  • 共识基于最新循证医学证据,针对PARP抑制剂在乳腺癌治疗中的规范应用和安全性管理制定指导意见。

临床怎么用

  • 为临床实践中PARP抑制剂在乳腺癌的规范应用和安全性管理提供参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Breast cancer poses a major threat to women's health in China, with its incidence rate continuously rising, leading to an increasing disease burden and an urgent need for novel and effective treatment strategies. In recent years, poly ADP-ribose polymerase (PARP) inhibitors, as a new class of anti-tumor drugs targeting the DNA damage repair pathway, have demonstrated significant efficacy in the treatment of breast cancer with BRCA1/2 mutations. These agents induce a "synthetic lethality" effect by specifically inhibiting DNA repair in tumor cells, offering a new option for precision therapy. Currently, PARP inhibitors such as olaparib and fluzoparib have been approved for clinical use. Based on the latest evidence-based medical data, the Professional Committee on Clinical Research of Oncology Drugs, China Anti-Cancer Association, Expert Committee for Monitoring the Clinical Application of Antitumor Drugs and Breast Cancer Expert Committee of National Cancer Quality Control Center, Cancer Chemotherapy Quality Control Expert Committee of Beijing Cancer Treatment Quality Control and Improvement Center have jointly organized and invited domestic oncology experts with rich diagnosis and treatment experience as well as relevant interdisciplinary experts to compile the "Expert consensus on the clinical application of PARP inhibitors in breast cancer (2025 edition)". This consensus aims to provide guidance on the standardized application and safety management of PARP inhibitors in breast cancer treatment, with the goal of supporting clinical practice. 乳腺癌是中国女性健康的重大威胁,其发病率持续攀升,导致疾病负担不断加重,对新型有效治疗策略的需求日益迫切。近年来,聚腺苷二磷酸核糖聚合酶(PARP)抑制剂作为靶向DNA损伤修复通路的新型抗肿瘤药物,在乳腺癌易感基因1/2突变的乳腺癌治疗中展现出显著疗效。PARP抑制剂这类药物通过特异性抑制肿瘤细胞的DNA修复,产生合成致死效应,为精准治疗提供了新选择。目前,已有奥拉帕利、氟唑帕利等PARP抑制剂获批用于临床治疗。共识基于最新循证医学证据,中国抗癌协会肿瘤药物临床研究专业委员会、国家抗肿瘤药物临床应用监测专家委员会、国家肿瘤质控中心乳腺癌专家委员会联合北京市肿瘤治疗质量控制和改进中心肿瘤化疗质控专家委员会,共同组织邀请国内具有丰富诊疗经验的肿瘤专家和相关跨学科专家共同撰写《乳腺癌PARP抑制剂临床应用专家共识(2025版)》,针对PARP抑制剂在乳腺癌治疗中的规范应用和安全性管理制定指导意见,以期为临床实践提供参考。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. [Expert consensus on the clinical application of PARP inhibitors in breast cancer (2025 edition)]. Zhonghua Zhong Liu Za Zhi. 2026. PMID: 42086517. doi:10.3760/cma.j.cn112152-20251027-00530

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。